Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
2상
완료
NCT03472586
| 대상 질환 | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 14 명 |
|---|
| 중재(약물) | Ipilimumab, Nivolumab, Embolization Therapy |
|---|
| 시작일 | 2018년 5월 2일 |
|---|
| 완료일 | 2022년 12월 31일 |
|---|
| 결과 공개일 | 2023년 11월 29일 |
|---|
요약
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. · Participants
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 8 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 5 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 1 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.